- $246.83m
- $500.89m
- $715.07m
- 67
- 88
- 66
- 87
Annual income statement for 8x8, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 532 | 638 | 744 | 729 | 715 |
| Cost of Revenue | |||||
| Gross Profit | 302 | 391 | 502 | 504 | 485 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 678 | 792 | 792 | 758 | 712 |
| Operating Profit | -146 | -154 | -47.7 | -29.4 | 2.87 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -165 | -176 | -70.3 | -64 | -24.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -166 | -175 | -73.1 | -67.6 | -27.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -166 | -175 | -73.1 | -67.6 | -27.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -166 | -175 | -73.1 | -67.6 | -27.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.55 | -1.48 | -0.709 | -0.488 | -0.198 |